QBiotics Group

  • About
    • Our Company
    • Leadership Team
    • Corporate Social Responsibility
    • Corporate Governance
  • Our Portfolio
    • Pipeline
    • Human Oncology
    • Wound Healing
    • Preclinical
    • STELFONTA®
  • Science
    • Our Science
    • Publications & Presentations
  • Investor Centre
    • Investor information
    • Announcements
  • Media
    • News & Media
    • Media Kit
  • Contact
Register for
updates

News & Media

European approval for QBiotics tigilanol tiglate
Biotech Dispatch
21 Jan 2020
Read More
Anticancer candidate trialled in solid tumours
Lab Online
10 Jan 2020
Read More
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
BioSpace.com
12 Dec 2019
Read More
QBiotics updates on publication of tigilanol tiglate trial results
Biotech Dispatch
10 Dec 2019
Read More
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours
BioSpace.com
09 Dec 2019
Read More

Page 3 of 3

  • 1
  • 2
  • 3

QBiotics Group
PO Box 42
Toowong BC, QLD 4066
Australia

Privacy policy

Terms of use

Counterfeit products disclaimer

 

© QBiotics. All Rights Reserved.